Pharmaceutical Asset, Franchise, and Portfolio Strategy
Rosa’s Pharmaceutical Strategy Process is an effective means of gaining insight into key strategic decisions, optimizing the learning that is at the heart of development strategy, and accelerating organizational decision making. We address difficult strategic decisions at all levels during clinical development:
- Asset Strategy to optimize how individual assets are developed and quantify their value
- Franchise Strategy to evaluate assets and other opportunities in a therapeutic franchise and identify the best strategy for growth and value creation
- Portfolio Strategy to manage uncertainty in the corporate portfolio and achieve corporate growth goals.
Rosa’s rigorous approach to strategy is aimed squarely at the Proof of Concept stage (Late Preclinical to Phase IIb). It is in these early development phases, in which uncertainty is greatest and clarity of direction is lacking, that decisions can make or break a product’s – or a company’s – future.
Our unique competency is our ability to understand the uncertainty (or risk) in a strategic situation and to integrate powerful decision-analytic approaches to make outcomes more predictable and more valuable.
In a typical strategy assignment, the Rosa team works with the client to bring clarity to the right direction to move forward. We work to build consensus with organizational alignment, resulting in effective execution of the chosen strategy. Most assignments bring about a redeployment of underused client resources, and usually we find that the most valuable strategic alternative is one that had not been thought of before the start.
Rosa’s leaders have decades of experience helping pharmaceutical, biotech, diagnostic and medical device companies of all sizes make better strategic decisions. They were responsible in the 1990s for developing the portfolio management and economic modeling methodologies now accepted as pharmaceutical industry standards. Rosa continues to push the state of the art forward.
A fundamental tenet of Rosa’s strategy practice is to work with clients to help them develop better in-house decision-making capability.
For more information, see the following:
- Key Questions for Pharmaceutical Strategy
- Compound Lifecycle Planning
- Program Design
- Licensing Valuation
- Market Assessment and Competitive Analysis
- Strategic Portfolio Management
To discuss how Rosa & Co might help your company, please contact:
Ron Beaver, PhD
Executive Vice President
services@rosapharma.com